Suzdak Peter David 4
4 · REXAHN PHARMACEUTICALS, INC. · Filed Jan 30, 2018
Insider Transaction Report
Form 4
Suzdak Peter David
Chief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2018-01-26+112,271→ 112,271 totalExercise: $2.29Exp: 2028-01-26→ Common Stock (112,271 underlying)
Footnotes (1)
- [F1]One quarter of the option vests and becomes exercisable on January 26, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested.